Effect at One Year of Adjuvant Trastuzumab for HER2+ Breast Cancer Combined with Radiation or an Anthracycline on Left Ventricular Ejection Fraction.
Journal
The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277
Informations de publication
Date de publication:
15 06 2020
15 06 2020
Historique:
received:
21
01
2020
revised:
09
03
2020
accepted:
10
03
2020
pubmed:
26
4
2020
medline:
1
9
2020
entrez:
26
4
2020
Statut:
ppublish
Résumé
To determine the impact of radiation therapy (XRT) in addition to trastuzumab (TZB) adjuvant chemotherapy for HER2+ breast cancer on left ventricular systolic function, we assessed demographics, oncologic treatment history including XRT exposure, and serial measurements of left ventricular ejection fraction (LVEF) in 135 consecutively identified women receiving TZB for treatment of adjuvant breast cancer. Longitudinal mixed effects models were fit to identify baseline to treatment changes in LVEF among those receiving TZB with or without concomitant anthracycline or XRT. Women averaged 53 ± 3 years in age, 77% were white, 62% patients had 1 or more cardiovascular risk factors at baseline, and mean duration of TZB was 11 ± 5 months. Seventy-seven women were treated with XRT and received between 4000 and 5500 cGy of radiation. The LVEF declined by an average of 3.4% after 1 year for those in the study. Relative to baseline upon completion of adjuvant TZB, LVEF remained reduced for those receiving anthracycline with or without XRT (p=0.002 for both), or XRT alone (p=0.002), but not in those without these therapies. Amongst patients treated only with XRT and TZB, LVEF declined 3.1% on average in those with left-sided disease and 6.9% on average in those with right-sided disease (p= 0.06, p= 0.008 respectively). Among women receiving TZB for adjuvant treatment of HER-2 positive breast cancer, the administration of XRT, anthracycline, or the combination of the 2 is associated with a persistent post-treatment as opposed to a temporary treatment related decline in LVEF.
Identifiants
pubmed: 32331711
pii: S0002-9149(20)30262-9
doi: 10.1016/j.amjcard.2020.03.013
pmc: PMC8051140
mid: NIHMS1586714
pii:
doi:
Substances chimiques
Anthracyclines
0
Antineoplastic Agents, Immunological
0
Receptor, ErbB-2
EC 2.7.10.1
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1906-1912Subventions
Organisme : NCI NIH HHS
ID : R01 CA167821
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA199167
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL118740
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Semin Oncol. 2000 Dec;27(6 Suppl 11):9-14; discussion 92-100
pubmed: 11236034
J Clin Oncol. 2005 Nov 1;23(31):7811-9
pubmed: 16258083
Eur J Clin Invest. 2016 Mar;46(3):264-84
pubmed: 26728634
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):836-44
pubmed: 26530752
J Clin Oncol. 2005 Nov 1;23(31):7820-6
pubmed: 16258084
JAMA. 2003 May 21;289(19):2560-72
pubmed: 12748199
Pharmacol Rev. 2004 Jun;56(2):185-229
pubmed: 15169927
Diabetes Care. 2010 Jan;33 Suppl 1:S62-9
pubmed: 20042775
Breast Cancer Res Treat. 2019 Feb;174(1):179-185
pubmed: 30478787
Hum Exp Toxicol. 2017 Nov;36(11):1121-1130
pubmed: 27932539
J Clin Oncol. 2005 Oct 20;23(30):7475-82
pubmed: 16157933
Am J Cardiol. 1981 May;47(5):1061-7
pubmed: 7223652
Intern Emerg Med. 2016 Feb;11(1):123-40
pubmed: 26712595
Ann Oncol. 2008 Jun;19(6):1110-6
pubmed: 18344537
Circulation. 2017 Apr 11;135(15):1397-1412
pubmed: 28104715
J Clin Oncol. 2004 Jan 15;22(2):322-9
pubmed: 14722042
Exp Clin Cardiol. 2011 Fall;16(3):70-4
pubmed: 22065936
Radiother Oncol. 2009 Jan;90(1):122-6
pubmed: 18976826
J Clin Oncol. 2007 Sep 1;25(25):3859-65
pubmed: 17646669
Am J Cardiol. 2017 May 15;119(10):1637-1642
pubmed: 28341361
J Clin Oncol. 2009 Jun 1;27(16):2638-44
pubmed: 19349549
Cancer. 2002 Oct 1;95(7):1592-600
pubmed: 12237930
J Clin Oncol. 2008 Aug 1;26(22):3777-84
pubmed: 18669466
Radiol Oncol. 2014 Apr 25;48(2):105-12
pubmed: 24991199
Circ Heart Fail. 2012 Mar 1;5(2):183-90
pubmed: 22361079
Circulation. 2014 Nov 4;130(19):1749-67
pubmed: 25070666
Circ Cardiovasc Imaging. 2012 Sep 1;5(5):596-603
pubmed: 22744937
Circulation. 2002 Apr 2;105(13):1551-4
pubmed: 11927521